Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.

CYSTOID MACULAR EDEMA

Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

Ranibizumab,

Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.

Triamcinolone acetonide

Soll Eye

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

To assess the safety of intravitreal R and T for the treatment of acute pseudophakic cystoid macular edema by evaluating:
Incidence and severity of ocular adverse events, as identified by eye examination
Incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs

Mean change in spectral domain OCT CMT from baseline (microns)

Mean change in ETDRS letters from baseline (letters)

Proportion of patients with 3 line or better ETDRS letter improvement (%)

Time to 3 line ETDRS letter improvement (days)

Genentech, Inc.

Cholera

Diarrhea

Vibrio Infections

up to 1 x 10^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once

Peru-15 Vaccine

25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)

Placebo

International Centre for Diarrhoeal Disease Research, Bangladesh

Christian Medical College

Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants

A Multi-site, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Trehalose-reformulated Peru-15 (Choleragarde)Vaccine Given Simultaneously With Measles Vaccine in Healthy Indian and Bangladeshi Infants

trehalose/nausea

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum